ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.85 USD
-0.14 (-7.04%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Brokerage Reports
0 items in cart
ProQR Therapeutics N.V. [PRQR]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Gene Juice: RNA Editing Rises to the Forefront of RNA Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Highlighting Axiomer Potential as Lead ADAR Programs Remain on Track to Enter Clinics
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
AX-1412 Might Unlock the Potential of EONS for Cardiovascular Diseases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Platform Updates and Looking to the Future of Axiomer Pipeline; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Axiomer Platform Defines Next Chapter For RNA Therapeutic Focus; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Axiomer Clarity Sets Next Stages For RNA-Editing Platform; Reit Buy and PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Axiomer RNA Platform Remains Focus-Initial Targets Anticipated Early 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Strategic Focus Shifts to Axiomer RNA Platform-Targets on 2022 Horizon; PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Axiomer Platform and Ultevursen Regulatory Discussions Can Define 2022 Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Considerations Beyond ILLUMINATE Trial; Restructuring, Axiomer Clarity Expected 2H22; PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Shifting Focus Beyond Sepofarsen-Upcoming 2022 Platform Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 2/3 Sepofarsen Top Line Miss Shifts Strategic Focus; PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Considerations For Approaching Phase 2/3 Sepofarsen Top-Line
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Sepofarsen Leads RNA Therapy Advancement - State of the Union
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Sepofarsen LCA-10 Readout Expected Near-Term; RNA Platform Broadens Reach
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Axiomer Collaboration Yields Opportunity for Broader RNA Editing Validation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Steady As She Goes - RNA Therapy Platform Poised for Multiple Shots On Goal
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ProQR Therapeutics N.V.
Industry: Medical - Biomedical and Genetics
Our Thoughts on Forthcoming Data Readouts; Advancement Across RNA Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A